Intranasal inoculation of *Mycoplasma pulmonis* in mice with severe combined immunodeficiency (SCID) causes a wasting disease with grave arthritis

B. EVENGÅRD*, K. SANDSTEDT*, G. BÖLSKE†, R. FEINSTEIN†, I. RIESENFELT-ÖRN* & C. I. E. SMITH*‡ *Department of Immunology, Microbiology, Pathology and Infectious Diseases, Karolinska Institute, Huddinge Hospital, Huddinge, †National Veterinary Institute, Uppsala, and ‡Centre for BioTechnology, Karolinska Institute, Huddinge, Sweden

(Accepted for publication 23 September 1994)

SUMMARY

Mycoplasma pulmonis or Myc. pneumoniae were inoculated intranasally to C.B-17 scid/scid mice (severe combined immunodeficient (SCID) mice). Immunocompetent C.B-17 mice were inoculated as controls. During the observation period of 5 weeks the mice were killed and necropsied. Mycoplasma pulmonis was recovered from all of the inoculated mice, and dissemination to various tissues increased with time. SCID mice, unlike immunocompetent mice, did not show lung lesions but exhibited severe inflammatory changes of the joints. Mycoplasma pulmonis, however, was isolated both from the lungs and the articular lesions. In addition, SCID mice infected for more than 3 weeks suffered from a pronounced loss of weight and emaciation. In the experiment with Myc. pneumoniae the agent could be reisolated, but lesions were not found in any of the infected mice. Mycoplasma pulmonis infection in SCID mice may be useful as a model of arthritis in immunodeficient humans.

Keywords scid mice arthritis Mycoplasma pulmonis Mycoplasma pneumoniae

INTRODUCTION

Mycoplasmas are ubiquitous organisms that may infect animals and man, and can contaminate cell cultures. The course of mycoplasmal infections can be influenced by various factors, a major one being the immune system of the host. In immunodeficient patients mycoplasmas can act as opportunists. Mycoplasmas generally occurring in the urogenital or respiratory tract have been found to cause arthritis and sometimes osteomyelitis in patients with hypogammaglobulinaemia [1-4].

The murine infection with *Mycoplasma pulmonis* resembles in many respects the human infection with *Myc. pneumoniae* [5,6]. *Mycoplasma pulmonis* is a rodent pathogen with an affinity for the mucosal cell surfaces. *Mycoplasma pulmonis*infected animals frequently suffer from lesions in the respiratory tract, but the reproductive organs, joints, and brain can also be affected [7]. The natural course of rodent mycoplasmosis depends on the immune status of the animal, reflected by age, species, and strain. The disease can be subclinical as well as overt and sometimes lethal. In terminal stages there is weight

Correspondence: K. Sandstedt, Department of Immunology, Microbiology, Pathology and Infectious Diseases, Karolinska Institute, Huddinge Hospital, S-141 86 Huddinge, Sweden. loss, roughened hair coat, nasal discharges, and dyspnoea. Experimental infection with Myc. *pulmonis* in mice produces rhinitis, otitis, laryngotracheitis and an acute alveolar pneumonia with a rich infiltration of neutrophils and a high mortality. Surviving animals may develop a chronic disease. Lesions in the lungs are characterized by chronic inflammation with lymphoid hyperplasia [8,6]. If Myc. *pulmonis* is inoculated intravenously arthritis can occur [9,10].

Nude animals, i.e. mice and rats with T cell deficiency, have been used to investigate the immune response to mycoplasma organisms. Nude mice intranasally infected with Myc. pulmonis developed arthritis [10] and parenteral infection with Myc.pulmonis resulted in more severe arthritis in athymic nude mice than in normal mice. Furthermore, in athymic animals larger numbers of Myc. pulmonis organisms could be isolated from joints and spleens and the infection persisted for a longer time [11].

The mutation severe combined immunodeficiency (scid) is characterized by the virtual absence of functional B and T lymphocytes, due to a defect in the mechanisms responsible for the rearrangement of antigen receptor genes [12,13]. The aim of this investigation was to describe the lesions caused by Myc. pulmonis in scid mice. Although mice are not natural hosts of Myc. pneumoniae [14], infections with Myc. pneumoniae were also performed, to evaluate the susceptibility of the scid mouse to this organism, and to explore the possibility of developing a murine model of the infection.

MATERIALS AND METHODS

Mice

Scid mice, males, 7 weeks old, were obtained from a breeding colony at Stockholm University and from Bommice (Ry, Denmark). The animals from the colony at Stockholm University were intermittently given prophylactic treatment with trimethoprim and sulfadoxin in the drinking water to protect against *Pneumocystis carinii* infection. Animals from Bommice were not treated with antibiotics, and remained free from *P. carinii* throughout the study. During the experiment the mice were housed in sterilized plastic boxes provided with high efficiency air filters (environmental conditions in the isolator: temperature 22°C, relative humidity 60%, 12h light:12h dark schedule), and had free access to sterilized pellets and water.

Mycoplasma strains

Mycoplasma pulmonis, M 195/82, was isolated from a mouse with pneumonia and had been passaged four times before being stored at -70° C. *Mycoplasma pneumoniae*, M28/92, was isolated from a patient sputum sample and had been passaged three times before being stored at -70° C.

Mycoplasma cultivation

Broth for cultivation was composed of 300 ml Hanks' balanced salt solution (HBSS), 450 ml glass-distilled water, 4.9 g Bacto-Brain Heart Infusion (Difco, Detroit, MI), 5.2 g Bacto-PPLO Broth w/o CV (Difco), 35 ml fresh yeast extract, 100 mg ampicillin (Astra, Södertälje, Sweden), 2.8 ml 0.5% phenol red, 2.0 ml 5% thallium acetate, and 185 ml heat-inactivated horse serum. The pH was adjusted to 7.4. For solid medium 0.6% agarose (Marine Colloids, Rockland, MN) was added. Pure inoculates were cultured without thallium acetate and ampicillin. Tissue samples, 0.1 g, were ground in a mortar in 2.7 ml broth. The cotton wire swabs were immersed in 2.7 ml broth and left for 1 h. From these and from the tracheobronchial washings 0.01 ml was streaked to plates. For each animal, pooled sample suspensions were inoculated to broth in 10-fold serial dilutions to 10^{-4} . Plates were incubated 7 days in an atmosphere with 5% CO₂. The broth samples were incubated for 21 days or until they showed an unequivocal change in pH, when they were subcultured on agar. From one of the highest dilutions showing pH change subculture was also made in broth. After detection of mycoplasma colonies on the plates the isolates were identified by immunofluorescence on unfixed agar colonies, using antisera against Myc. pulmonis and Myc. pneumoniae, respectively.

Histological preparation

Tissue specimens were fixed by immersion in 10% buffered formalin pH 7.4 for 24 h, approximately. The skull and bones were decalcified by immersion in Christensen's fluid until softened. Tissue specimens were processed routinely and stained with haematoxylin and eosin. Sections of the nasal mucosa, lung, and joints were also stained with the Giemsa stain. In addition, selected sections from lung tissues were stained with the Warthin–Starry (silver) stain, to exclude the presence of the ciliae-associated respiratory (CAR) bacillus.

Preparation of inoculate

The strains were thawed and cultured until the acid pH shift appeared in the broth after 1-3 days. The numbers of colony-forming units (CFU)/ml broth were determined. Before inoculation the cultures were appropriately diluted with PBS.

Experimental design

In the first experiment 14 *scid* mice and three C.B-17 mice were inoculated through the nose with *Myc. pulmonis*. Additionally, two uninfected *scid* mice were killed as controls. The *scid* mice were randomly allocated into three groups, exposed to 10^5 CFU, 10^4 CFU and 10^2 CFU (five, four and five *scid* mice were allocated in each group, respectively). One mouse from each group given 10^5 CFU and 10^2 CFU was then killed at postinfection days 6, 13, 20, 24 and 35. The *scid* mice infected with 10^4 CFU were killed at day 30, except one who died at day 25. The C.B-17 mice were killed at post-infection day 38.

In the other experiment 12 scid mice and five C.B-17 mice were given Myc. pneumoniae intranasally. Six of the scid mice and three of the C.B-17 mice received 10^5 CFU, and the other mice 10^3 CFU. Five scid mice and two C.B-17 mice served as uninfected controls. Infected animals were killed after 6, 13, 20, 27 and 34 days, respectively.

In both experiments the mice were necropsied immediately after euthanasia by CO_2 inhalation. Samples for histopathological examination and mycoplasma isolation were obtained from the nasal mucosa, trachea, bronchi, lung, spleen, and the coxofemoral and the knee joints. Cultural samples from the nasal mucosa and the articular surfaces were collected by thorough swabbing. The trachea and bronchi were sampled by washing the mucosa with culture media injected into the lumen. The samples from the other tissues consisted of cut tissue blocks. Gross lesions found in other tissues were also examined histologically and cultured.

RESULTS

Mycoplasma pulmonis infection in scid mice

The findings in mice infected with Myc. pulmonis are summarized in Table 1. Body weights of infected scid mice were decreased. During the first 20 days after infection this was expressed as a retardation of growth, and later on as a pronounced loss of weight and emaciation. Mycoplasma pulmonis was recovered from all of the inoculated mice. In C.B-17 mice Myc. pulmonis was solely reisolated from the respiratory organs, which was also the site affected by lesions. In scid mice dissemination of Myc. pulmonis increased with time. Mycoplasma pulmonis was recovered from the nasal mucosa, trachea, lung, joints, spleen, kidney, and middle ear. The animals treated with trimethoprim and sulfadoxin (scid L217-330) showed the same pattern as untreated animals. Despite widespread colonization of tissues by Myc. pulmonis, the main lesions were found in the joints. Lesions in the lungs were not observed. However, the nasal mucosa showed pathological signs. Gross changes were not evident, but histological examination revealed focal degeneration of the nasal epithelium, mucusal oedema, and a discrete infiltration of the nasal mucosa with neutrophils and monocytes. In other tissues changes were not noticed. Mice killed at post-infection day 13 did not show lesions. Moderate lesions of rhinitis in scid mice were also found histologically at 20, 24, and 30 days post-infection. One scid mouse found dead

weight (g)DaystNoseTracheaLungJointsSpleenOther organsOther236++++++++HNeal mucosa246++++++HNENENeal mucosa2313+++++HNENENegative245++++HNENENegative2313++++HNENENegative24+++++NENENegative2520+++++NENENegative2120+++++NENegative2120+++++NENegative10-1230+++++NENegative10-1230++NENENENegative10-1230++++NENE10-1230++++NENegative10-1230+++NENENegative10-1230+++++NENegative10-1230++++++NENegative10-1230++++++NENe10-1230++NENENENENE10-1238++	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		Dece of	Body				M yc. pumonis cumu					Histological examination	ion
				DOSE 01 infaction	bouy weight*							Other		þ	
			Mouse	(CFU)	(g)	Days†	Nose	Trachea	Lung	Joints	Spleen	organs	Nasal mucosa	Bronchi, trachea, lung	
			scid I 248	105	25	6	+++++	+	1	NE	BE	NE	Moderate rhinitis	Lung: negative	NE
			scid I 240	102	74	, v	+	+	ł	NE	NE	NE	Negative	Lung: negative	NE
			scid 1.220	105	1 2	° "	+	+	+	NE	ł	NE	Negative	Negative	NE
	0 2 2 2 1		SCIU 1200	102	77	: "	+++++++++++++++++++++++++++++++++++++++	+	+	NE	I	NE	Negative	Lung: perivascular	NE
	$ \begin{bmatrix} 10^{\circ} & 21 & 20 & ++ & + & NE & - & NE & Severe thinitis Negative erricht in the interval of the interva$	$ \begin{bmatrix} 0^2 & 21 & 20 & ++ & + & NE & NE & - & NE & Severe thinitis \\ 0^2 & 1^2 & 2 & 20 & ++ & + & + & + & NE & - & Mederate thinitis \\ 0^2 & 1^2 & 2 & 2 & ++ & + & + & + & NE & + & Moderate thinitis \\ 0^2 & 10^{-1} & 2 & + & + & + & + & + & NE & NE & Moderate thinitis \\ 0^2 & 10^{-1} & 2 & + & + & + & + & + & + & NE & NE & Moderate thinitis \\ 0^2 & 10^{-1} & 3 & + & + & + & + & + & + & + & + & NE & NE$	SCIM 1713	2	5	2							•	monocyte infiltrates	
			scid 1.282	105	21	20	+ +	÷	NE	NE	I	NE	Severe rhinitis	Negative	NE
	$ \begin{bmatrix} 0^{2} & 17 & 24 & +++ & ++ & + & + & + & + & + & + & +$	$ \begin{bmatrix} 0 & 1 & 2 & 0 & 2 & +++ & ++ & + & + & + & + & + & + $	scid L284	10 ²	26	20	+ +	+ +	+ +	NE	I	Middle	Moderate rhinitis	Negative	NE
	$ \begin{bmatrix} 0^{2} & 17 & 24 & +++ & ++ & NE & +++ & NE & Moderate rhinits Lung regative \\ 10^{2} & 20 & 24 & +++ & ++ & NE & NE & NE & Moderate rhinits Lung regative \\ 10^{2} & 10-12 & 30 & ++ & NE & ++ & ++ & NE & Moderate rhinits Lung regative \\ 10^{2} & 10-12 & 30 & ++ & NE & ++ & ++ & ++ & NE & Moderate rhinits Lung regative \\ 10^{2} & 10-12 & 30 & ++ & NE & ++ & ++ & ++ & NE & Moderate rhinits Lung regative \\ 10^{3} & 18 & 35 & +++ & ++ & ++ & ++ & NE & Moderate rhinits Lung regative \\ 10^{3} & 18 & 35 & +++ & ++ & ++ & ++ & NE & Moderate rhinits Lung regative \\ 10^{3} & 18 & 35 & +++ & ++ & + & ++ & + & ++ & NE & Moderate rhinits Lung regative \\ 10^{3} & 18 & 35 & +++ & NE & ++ & + & + & + & + & + & + & + \\ 10^{3} & 22-23 & 38 & ++ & NE & ++ & + & + & + & + & + & NE & Mild trachetits Lung regative \\ 20 & 10^{4} & 22-23 & 38 & ++ & NE & ++ & + & + & + & + & + & + & + \\ 10^{4} & 22-23 & 38 & ++ & NE & ++ & + & + & + & + & + & + & + & + \\ 20 & 22-23 & 38 & ++ & NE & ++ & + & + & + & + & + & + & + & + &$	$ \begin{bmatrix} 0^{2} & 17 & 24 & +++ & ++ & NE & +++ & Moderate rhinits Lung regative \\ 10^{2} & 20 & 24 & +++ & ++ & NE & NE & NE & Moderate rhinits Lung regative \\ 10^{4} & 10-12 & 30 & ++ & NE & ++ & ++ & NE & NE & Moderate rhinits Lung regative \\ 10^{4} & 10-12 & 30 & ++ & NE & ++ & ++ & + & + & NE & Moderate rhinits Lung regative \\ 10^{4} & 10-12 & 30 & ++ & NE & ++ & ++ & + & + & + & + & + & NE & Moderate rhinits Lung regative \\ 10^{2} & 118 & 35 & +++ & ++ & + & + & + & + & + & + & +$										ear + + + +			
		$ \begin{bmatrix} 10^2 & 20 & 24 & +++ & + & NE & ++ & NE & Moderate rhinitis Negative \\ 10^4 & 10^{-1}2 & 33 & ++ & NE & ++ & + & NE & NE & Mild rhinitis Lung regative \\ 10^4 & 10^{-1}2 & 30 & ++ & NE & ++ & + & + & + & NE & NE & $	scid L303	10 ⁵	17	24	+ + +	+ + +	+ +	NE	+ +	Ear + + + +	Moderate rhinitis	Lung: negative	NE
	$ \begin{bmatrix} 10^{4} & 10^{-1} & 2 & 3 & + & NE & H & H & + & + & NE & NE & Mid rhinits & Lung: negative 10^{4} & 10^{-1} & 3 & + + & NE & NE & NE & Mid rhinits & Lung: negative 10^{4} & 10^{-1} & 3 & + + & + & + & + & + & + & + & + &$		scid L304	10^{2}	20	24	+ + +	+	+	NE	+ + +	NE	Moderate rhinitis	Negative	NE
	$ \begin{bmatrix} 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 &$			401	CI 01	30	4	NF	+ +	+	NF	NF	NE	Lung: negative	Severe arthritis
	$ \begin{bmatrix} 0 & 10-12 & 30 & + & NE & + & + & + & + & NE & NE & Multimum substructure in the initial integration is the initial integration in the initial integration integrated i$	$ \begin{bmatrix} 0^{\circ} & 10-12 & 30 & ++ & NE & ++ & + & + & NE & Mut minima & Lung. negative \\ 10^{\circ} & 10-12 & 30 & ++ & NE & ++ & + & + & + & + & NE & Moderate rhinitis & Lung. negative \\ 10^{\circ} & 10-12 & 30 & ++ & NE & ++ & + & + & + & + & + & NE & Moderate rhinitis & Lung. negative \\ 10^{\circ} & 18 & 35 & +++ & ++ & + & + & + & + & + & + & NE & Moderate rhinitis & Lung. negative \\ 10^{\circ} & 18 & 35 & +++ & NE & ++ & + & + & + & + & + & + & + & NE & Moderate rhinitis & Lung. negative \\ 10^{\circ} & 10^{\circ} & 22-23 & 38 & ++ & NE & ++ & + & + & + & + & + & NE & Mild trachetis & Lung. negative \\ 31 & 10^{\circ} & 22-23 & 38 & ++ & NE & ++ & - & - & NE & Moderate rhinitis & Severe bnochilis \\ 32 & 10^{\circ} & 22-23 & 38 & ++ & NE & ++ & - & - & NE & Moderate rhinitis & Mild broncholitis \\ 0 & 22 & 22-33 & 38 & ++ & NE & - & - & NE & Moderate rhinitis & Mild broncholitis \\ 0 & 23 & 0 & - & - & - & NE & Negative & Lung. negative \\ 0 & 21 & 0 & - & - & - & NE & Negative & Lung. negative \\ 0 & 21 & 0 & - & - & - & - & NE & Negative & Lung. negative \\ 0 & 21 & 0 & - & - & - & - & NE & Negative & Lung. negative \\ 0 & 21 & 0 & - & - & - & - & NE & Negative & Lung. negative \\ 0 & 21 & 0 & - & - & - & - & NE & Negative & Lung. negative \\ 0 & 21 & 0 & - & - & - & - & NE & Negative & Lung. negative \\ 0 & 21 & 0 & - & - & - & - & NE & Negative & Lung. negative \\ 10^{\circ} restructure lanasia. + Time elapsed between infection date and euthanasia. + + + + + + + + + + + + + + + + + + +$	scid Lolu	01	71-01	C 7	+ -						Maild thinking	I unar necotive	Canara arthritic
$ \begin{bmatrix} 10^4 & 10-12 & 30 & ++ & NE & ++ & + & + & + & NE & Severe rhmus & Lung: regative \\ 10^2 & 18 & 35 & +++ & + & + & + & + & + & + & + & + $	$ \begin{bmatrix} 0^{4} & 10-12 & 30 & ++ & NE & ++ & + & + & + & NE & Severe funuts & Lung: regative \\ 10^{4} & 10-12 & 30 & ++ & NE & ++ & + & + & + & + & NE & Moderate rhinits & Lung: negative \\ 10^{2} & 18 & 35 & ++ & + & + & + & + & + & + & + & NE & Moderate rhinits & Lung: negative \\ 10^{2} & 18 & 35 & ++ & + & + & + & + & + & + & + & NE & Mild trachetits & Lung: negative \\ 10^{2} & 18 & 35 & ++ & NE & + & + & + & + & + & + & NE & Mild rhinits & Severe bronchits \\ 20 & 10^{4} & 22-23 & 38 & ++ & NE & + & - & - & NE & Mild rhinits & Severe bronchits \\ 31 & 10^{4} & 22-23 & 38 & ++ & NE & + & - & - & NE & Moderate rhinits & Mild broncholitis \\ 10^{4} & 22-23 & 38 & ++ & NE & - & - & NE & Moderate rhinits & Mild broncholitis \\ 21 & 0 & 23 & 0 & - & - & - & NE & Negative & Lung: negative \\ 0 & 23 & 0 & - & - & - & NE & Negative & Lung: negative \\ 0 & 21 & 0 & - & - & - & NE & Negative & Lung: negative \\ 0 & 21 & 0 & - & - & - & NE & Negative & Lung: negative \\ 0 & 21 & 0 & - & - & - & NE & Negative & Lung: negative \\ 0 & 21 & 0 & - & - & - & NE & Negative & Lung: negative \\ 10 & 21 & 0 & - & - & - & NE & Negative & Lung: negative \\ 10 & 21 & 0 & - & - & - & NE & Negative & Lung: negative \\ 10 & 21 & 0 & - & - & - & NE & Negative & Lung: negative \\ 10 & 21 & 0 & - & - & - & NE & Negative & Lung: negative \\ 10 & 21 & 0 & - & - & - & NE & Negative & Lung: negative \\ 10 & 21 & 0 & - & - & - & NE & Negative & Lung: negative \\ 10 & 10 & - & - & - & - & NE & Negative & Lung: negative \\ 10 & 10 & - & - & - & - & NE & Negative & Lung: negative \\ 10 & 10 & - & - & - & - & - & NE & Negative & Lung: negative \\ 10 & 10 & - & - & - & - & - & NE & Negative & Lung: negat$		scid L626	104	10-12	30	+	NE	+ +	+	2F	Z I		Lung. negative	
			scid L627	10^{4}	10-12	30	+ +	NE	+ +	+	1	NE	Severe rhinitis	Lung: negative	Mild arthritis
	$ \begin{bmatrix} 10^{5} & 18 & 35 & ++++ & +++ & +++ & +++ & \text{Negative} \\ 10^{2} & 18 & 35 & +++ & ++ & ++ & ++ & ++ & \text{NE} \\ 10^{2} & 35 & +++ & ++ & ++ & ++ & ++ & \text{NE} \\ 10^{2} & 22-23 & 38 & ++ & \text{NE} & ++ & - & - & - & \text{NE} \\ 22-23 & 38 & ++ & \text{NE} & ++ & - & - & - & \text{NE} \\ 10^{4} & 22-23 & 38 & ++ & \text{NE} & - & - & - & \text{NE} \\ 22-23 & 38 & ++ & \text{NE} & - & - & - & - & \text{NE} \\ 22-23 & 38 & ++ & \text{NE} & - & - & - & - & \text{NE} \\ 22-23 & 38 & ++ & \text{NE} & - & - & - & - & - \\ 22 & 0 & 23 & 0 & - & - & - & - & - & - \\ 23 & 0 & - & - & - & - & - & - & - \\ 0 & 23 & 0 & - & - & - & - & - & - \\ 0 & 21 & 0 & - & - & - & - & - \\ 0 & 21 & 0 & - & - & - & - & - \\ 21 & 0 & - & - & - & - & - & - \\ 21 & 0 & - & - & - & - & - & - \\ 22 & 0 & 21 & 0 & - & - & - & - & - \\ 24 \text{Negative} & \text{Lung: negative} \\ \text{*Body weight at uthasia.} $		scid L628	104	10-12	30	+ +	NE	+ + +	+ +	+ +	NE	Moderate rhinitis	Lung: negative	Moderate arthrit
															Constant and the second
			scid L328	105	18	35	+ + +	+	+ + +	+ +	+ + +	Kidney + +	Negative	Lung: negative	
			scid L330	10^{2}	18	35	+ + +		+	+ + +	+ + +	NE	Mild tracheitis	Lung: negative	Severe arthritis
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	2910' $22-23$ 38++NE++NEModerate rhinitisWild bronchiolitis30 10^4 $22-23$ 38++NE++NEModerate rhinitisWild bronchiolitis31 10^4 $22-23$ 38++NE++NEModerate rhinitisMild bronchiolitis31 10^4 $22-23$ 38++NE++NEModerate rhinitisMild bronchiolitis31 10^4 $22-23$ 38++NENEModerate rhinitisMild bronchiolitis31 10^4 $22-23$ 38++NENEModerate rhinitisMild bronchiolitis0 23 0NENENegativeLung: negativeNegative0210NENegativeLung: negative610210NENegativeLung: negative620210NENegativeLung: negative620210NENegativeLung: negative630210NENegativeLung: negative640210NENegative		40.	50 00	٥¢	-	NIE	+ +	I	1	NF	Mild rhinitis	Severe bronchitis	Mild arthritis
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	30 10^4 $22-23$ 38 $++$ NE $++$ $ -$ NEModerate rhinitisMild bronchiolitis31 10^4 $22-23$ 38 $+$ NE $ NE$ Moderate rhinitisMild bronchiolitis31 10^4 $22-23$ 38 $+$ $ -$ 61 0 23 0 $ -$ 61 0 21 0 $ -$ <	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	C.B-17/L629	10.	67-77	٥ <u>٢</u>	+		-					Severe pneumonia	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	31 10^4 $22-23$ 38+NENEModerate rhinitisMild bronchiolitis31 10^4 $22-23$ 38+NE-NEModerate rhinitisPreomonia0 23^3 0NENENegativeLung: negative0230NENENegativeNegative0210NENegativeLung: negative610210NENegativeLung: negative620210NENegativeLung: negative630210NENegativeLung: negative640210NENegativeLung: negative650210NENegativeLung: negative661210NENegativeLung: negative670210NENegativeLung: negative6811NENENegativeLung: negative69110NENENegativeLung: negative6110NEN		404	, , , , , , , , , , , , , , , , , , ,	30	+ +	NF	+ +	I	I	NE	Moderate rhinitis	Mild bronchiolitis	Negative
		$ \begin{bmatrix} 0 & 23 & 0 & - & - & NE & - & NE & Negative & Lung: negative \\ 0 & 23 & 0 & - & - & - & NE & - & NE & Negative \\ 0 & 21 & 0 & - & - & - & - & NE & Negative & Lung: negative \\ 0 & 21 & 0 & - & - & - & - & - & NE & Negative & Lung: negative \\ 0 & 21 & 0 & - & - & - & - & - & NE & Negative & Lung: negative \\ 0 & 21 & 0 & - & - & - & - & - & NE & Negative & Lung: negative \\ 0 & 21 & 0 & - & - & - & - & - & - & NE & Negative & Lung: negative \\ 1 & 0 & 21 & 0 & - & - & - & - & - & NE & Negative & Lung: negative \\ 1 & 1 & 1 & 1 & 1 & 1 & 1 & 1 \\ 1 & 1 &$	C.B-1/L030	104	57-77	° %	-+	NE	. 1	I	I	NE	Moderate rhinitis	Mild bronchiolitis	Negative
	0 23 0 - - NE NE Negative Lung: negative 0 23 0 - - NE NE Negative Negative 0 21 0 - - NE NE Negative Negative 0 21 0 - - NE NE Negative Negative 0 21 0 - - - NE Negative Lung: negative 0 21 0 - - - NE Negative Lung: negative 61 0 21 0 - - - NE Negative Lung: negative 62 0 21 0 - - - NE Negative Lung: negative 62 0 21 0 - - NE Negative Lung: negative 63 0 - - - NE Negative Lung: negative		100711- 0 -0	2	} 1	2								Pneomonia	
	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Controls							!					
0 23 0 NE Negative Negative Negative 0 21 0 NE Negative Negative 0 21 0 NE Negative Lung: negative 1 0 21 0 NE Negative Lung: negative 62 0 21 0 NE Negative Lung: negative 62 0 21 0 NE Negative Lung: negative 1 0 NE Negative Lung: negative 1 0 NE Negative Lung: negative	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	scid L217	0	23	0	I	I	I	NE	I	NE	Negative	Lung: negative	NE
0 21 0 - - - NE Negative Lung: negative 0 21 0 - - - - NE Negative 61 0 21 0 - - - NE Negative 62 0 21 0 - - - NE Negative 63 0 21 0 - - - NE Negative	0 21 0 - - - NE Negative Lung: negative 0 21 0 - - - - NE Negative Lung: negative 61 0 21 0 - - - NE Negative Lung: negative 62 0 21 0 - - - NE Negative Lung: negative 62 0 21 0 - - - NE Negative Lung: negative 63 0 21 0 - - - NE Negative Lung: negative 64 0 - - - - - NE Negative Lung: negative 65 0 21 0 - - - NE Negative Lung: negative 66 1 0 - - - NE Negative Lung: negative 7 - - - - - NE Negative L		srid I 218	c	23	0	I	I	I	NE	I	NE	Negative	Negative	NE
0 21 0 - - - NE Negative Lung: negative 61 0 21 0 - - - - NE Negative 62 0 21 0 - - - - NE Negative 1 0 - - - - - NE Negative	0 21 0 - - - NE Negative 61 0 21 0 - - - NE Negative 62 0 21 0 - - - NE Negative 62 0 21 0 - - - NE Negative 63 0 21 0 - - - NE Negative 64 0 2 - - - NE Negative Lung: negative 65 0 21 0 - - - NE Negative Lung: negative 66 1 0 - - - - NE Negative Lung: negative 67 0 21 0 - - - NE Negative Lung: negative 68 1 1 - - - - NE Negative Lung: negative	0 21 0 - - - Negative Lung: negative 61 0 21 0 - - - NE Negative Lung: negative 62 0 21 0 - - - NE Negative Lung: negative 63 0 21 0 - - - NE Negative Lung: negative 64 0 21 0 - - - NE Negative Lung: negative 62 0 21 0 - - - NE Negative Lung: negative 64 0 - - - - - NE Negative Lung: negative 65 0 21 0 - - - NE Negative Lung: negative 66 1 - - - - NE Negative Lung: negative 7 - - - - - - NE NE NE	scid 1.559	• c	21	0	I	t	ł	I	I	NE	Negative	Lung: negative	Negative
0 21 0 - Lung: negative Lung: negative Lung: negative 0 21 0 NE Negative Lung: negative	0 21 0 - Lung: negative 0 21 0 NE Negative Lung: negative *Body weight at euthansia.	0 21 0 - - - NE Negative Lung: negative 0 21 0 - - - - NE Negative Lung: negative 0 21 0 - - - - NE Negative Lung: negative * Body weight at euthanasia. * #Body weight at euthanasia. * *	scid I 560	, c	21	0	ł	I	1	I	I	NE	Negative	Lung: negative	Negative
0 21 0 – – – – – Lung: negative Lung: negative	* Body weight at euthanasia.	0 21 0 - Lung: negative Lung: negative Lung: negative * Body weight at euthanasia. † Time elapsed between infection date and euthanasia.	C B-171 561	• -	12		I	I	I	I	I	NE	Negative	Lung: negative	Negative
			C.B-17L562	• •	21	0	I	ı	I	I	I	NE	Negative	Lung: negative	Negative
	* Body weight at euthanasia.	* Body weight at euthanasia. † Time elapsed between infection date and euthanasia.													

Table 1. Experimental infection in mice with Mycoplasma pulmonis

390

B. Evengård et al.




Fig. 1. Arthritis in the femorotibial joint of a *scid* mouse infected with *Mycoplasma pulmonis*. Necrosis and severe leucocytic infiltration of the synovial membrane (arrow) and the articular capsule. The articular cartilage is preserved (arrowhead). (ME: Meniscus \times 36.)

at 25 days post-infection and five *scid* mice necropsied at 30 and 35 days post-infection exhibited synovitis and polyarthritis. In these mice the joints in the pelvic limbs appeared swollen and oedematous. Histologically, the hallmark of the lesions examined was destruction of the intimal cells of the synovial membranes.

In addition to necrosis and ulceration of the synovial surface, pronounced leucocytic infiltrations in the articular tissues were also observed (Fig. 1). Neutrophils, monocytes, and macrophages were abundant. Mononuclear leucocytes with a rather large cytoplasm were also noticed, but these cells could not be accurately identified. Low numbers of mast cells, displaying a typical appearance, occurred in a perivascular location and also irregularly distributed in the inflamed tissues. The synovial space contained leucocytes, necrotic cells, amorphous debris, and fibrin, whereas the synovial membranes and the joint capsules appeared infiltrated by granulation tissue. Degeneration and necrosis of the articular cartilages was observed in most of the joints examined (Fig. 2). In some of these joints the bones showed extensive necrotic zones, involving the whole depth of the epiphysis. There were also horizontal splits, haemorrhages between the epiphysis and the physis, and reparative changes, in the form of a highly cellular fibrocartilagenous tissue proliferating from the articular capsule towards the edges of the necrotic areas (Fig. 2). Mononuclear cells and polykaryons resembling osteoclasts appeared on, or in the vicinity of the osseous surfaces, mixed with the

inflammatory exudate. In addition, lesions of arteriolitis with severe necrosis of the tunica media and tunica adventitia were found in isolated arterioles of the joints, periarticular tissues, brain, spleen, liver, and kidney, but not in the lungs. Other changes observed in the periarticular tissues were tendinitis, myositis, and regeneration of muscle fibres.

Mycoplasma pulmonis infection in immunocompetent C.B-17 mice

The immunocompetent C.B-17 mice exhibited inflammatory reactions in the respiratory organs. At necropsy, one mouse displayed grey and red areas suggestive of lung consolidation. Histology confirmed the macroscopical findings, and revealed changes also in the other two mice examined. The nasal mucosa, bronchi, and the peribronchial lung tissues were heavily infiltrated by monocytes, macrophages, and lymphocytes, and the bronchial lumen contained numerous neutrophils, mixed with mucus, desquamated epithelial cells, necrotic cells, and debris. Other lesions found in the lung tissues were haemorrhages, necrosis of the alveolar epithelium, and perivascular infiltrations of mononuclear leucocytes, mostly lymphocytes, monocytes, and plasma cells. In the peripheral areas of the lung there were accumulations of large cells with a foamy cytoplasm that resembled histiocytes. Mild arthritis was observed in one C.B-17 mouse. However, as we were unable to isolate Myc. pulmonis from the joint the cause of the arthritis is not clear.




Fig. 2. Arthritis in the femorotibial joint of a *scid* mouse infected with *Mycoplasma pulmonis*. Severe necrotic changes in the articular and the epiphyseal cartilages cause ulceration of the articular surface (arrowheads). Ongoing reparative process is suggested by the highly cellular fibrocartilagenous tissue (arrows) proliferating from the periphery of the joint towards the edges of the necrotic zone. (ME: Meniscus $\times 144$.)

Mycoplasma pneumoniae *infection in scid and in C.B-17 mice* Results from infection with *Myc. pneumoniae* are presented in Table 2. *Mycoplasma pneumoniae* was recovered from the respiratory tract in 11 out of 12 infected *scid* mice and in three out of five infected C.B-17 mice. No *Myc. pneumoniae* was isolated from the spleen or joint samples. Significant gross or histological changes were not found in any of these mice.

Uninfected controls

In both of the experiments the uninfected control mice, *scid* as well as C.B-17, did not show growth of mycoplasmas or significant pathological changes.

DISCUSSION

Mycoplasma pulmonis produced a progressive disease in *scid* mice characterized by emaciation, arthritis, and lack of pulmonary pathology. The changes found in our immunocompetent mice are in keeping with the results of previous investigations where lesions of the respiratory organs are salient findings [6,8]. The disorder induced by *Myc. pulmonis* in *scid* mice also differs from mycoplasmosis as it has been described in other strains of immunodeficient mice. Davidson *et al.* [15] reported lung lesions in C3H/HeJ *scid* mice infected

with Myc. pulmonis. The use of different scid mouse strains may be one explanation of this divergence in results. However, the lack of detailed information about the lesions makes a thorough comparison impossible. Arthritis has been noticed in athymic mice after intranasal inoculation [6,10,11], and also after intravenous injections of Myc. pulmonis in immunocompetent mice [10] and rats [16,17].

In the present study Myc. pulmonis was given intranasally. The lesions of arteriolitis in various tissues of the scid mice suggest that Myc. pulmonis disseminated to distant tissues via the blood stream. The scid mutation does not affect the differentiation of myeloid cells [18], but it is likely that the lack of specific immunity allowed Myc. pulmonis to gain access to, and to settle in the articular tissues. It has been demonstrated that anti-mycoplasma antibodies protect from arthritis induced by Myc. pulmonis in a variety of mouse strains [19]. In humans also the humoral immune system seems to give protection against mycoplasma arthritis, as these disorders are frequently found in patients with hypogammaglobulinaemia [1-4]. In mice, defects in the complement system have been reported to result in enhanced susceptibility to mycoplasma arthritis [20]. Mycoplasma pulmonis may cause direct damage to the synovial tissues, via diverse mechanisms, such as lesions to host cell membranes, production of toxic metabolites, forma-

Mouse	Dose of infection (CFU)	Body weight* (g)	Days†	Myc. pneumoniae culture Nose, trachea, lung (pooled samples) (CFU recovered/ml sample)	Myc. pneumoniae culture Joints, spleen (pooled samples)	Histological examination Nasal mucosa, lung, joints
scid L388	10 ³	25	6	0	0	Moderate rhinitis
scid L389	10 ⁵	25	6	10 ³	0	Negative
scid L392	10 ³	26	13	> 10 ⁴	0	Negative
scid L393	10 ⁵	25	13	> 10 ⁴	0	Negative
scid L400	10 ⁵	27	20	10 ²	0	Negative
scid L401	10 ³	25	20	10 ³	0	Negative
scid L411	10 ³	24	27	10 ²	0	Negative
scid L412	10 ⁵	25	27	10 ³	0	Negative
scid L413	10 ³	27	34	10 ³	0	Negative
scid L414	10 ³	29	34	> 10 ⁴	0	Negative
scid L415	10 ⁵	27	34	> 10 ⁴	0	Negative
scid L416	10 ⁵	26	34	10 ³	0	Negative
C.B-17L390	10 ³	25	6	10 ³	0	Negative
C.B-17L391	10 ⁵	26	6	0	0	Negative
C.B-17L402	10 ⁵	28	20	> 10 ⁴	0	Negative
C.B-17L417	10 ³	28	34	10 ³	0	Negative
C.B-17L418	10 ⁵	27	34	0	0	Negative
Controls						
scid L378	0	25	0	0	0	Negative
scid L379	0	23	0	0	0	Negative
scid L440	0	28	41	0	0	Negative
scid L441	0	26	41	0	0	Negative
scid L442	0	28	41	0	0	Negative
C.B-17L377	0	25	0	0	0	Negative
C.B-17L439	0	27	41	0	0	Negative

Table 2. Experimental infection in mice with Mycoplasma pneumoniae

* Body weight at euthanasia.

† Time elapsed between infection date and euthanasia.

tion of peroxides, and competition with the host cells for nutrients [6]. It can also induce release of hydrolytic enzymes from mouse macrophages [21].

In addition to the protective features of different parts of the immune system, others causing tissue damage must be considered. The absence of immunocompetent lymphocytes in *scid* mice argues against the occurrence of cross-reactions reported [22] between *Myc. pulmonis* and the synovial tissues of mice. In *scid* mice, natural killer (NK) cell activity is not affected [23]. NK cells have a potent cytotoxic and antibacterial activity which does not require previous sensitization or antigen presentation by accessory cells, and in histological sections the NK cell resembles a lymphocyte with a large cytoplasm [24]. Mononuclear leucocytes, resembling NK cells, were noticed in the articular lesions of our *scid* mice, but we could not identify these cells more accurately as NK cells. The role of the innate immune system for the production of joint lesions needs further investigation.

Immune factors seem to be important in the development of lung injury caused by mycoplasmas. The lack of lung pathology despite the heavy load of Myc. pulmonis in our scid mice, together with reports of lung lesions in mycoplasma-infected athymic mice [6] indicates that immunoglobulins contribute to the genesis of the pneumonia. Mycoplasma pulmonis has a mitogenic effect upon mouse [25] and rat lymphocytes, and a

strong correlation between the combined T and B cell mitogenicity and lung pathogenicity has been reported [26]. Scid mice, lacking lymphocytes, consequently would be unable to respond to this mitogenicity. Growth of bacteria in the lung of scid mice in combination with lack of pulmonary pathology has been noticed previously. Mycobacterium bovis causes epithelioid granulomas in livers, spleens, and lungs of immunocompetent mice, but in scid mice the mycobacteria were located mostly in isolated alveolar macrophages, and granulomas were seen only in the spleen and liver [27].

A consequence of Myc. pulmonis infection in scid mice was a dramatic loss of weight. The reasons for this phenomenon are unknown, but factors like decreased food intake, competition for cell nutrients, and also release of cytokines, for instance tumour necrosis factor (TNF), may have been involved.

Mycoplasma pneumoniae infection of mice has been reported previously in immunocompetent mice [14] with absence, or only transient appearance, of lung lesions. In these studies, the colonization was poor and self-limiting, but in our study the recovery of *Myc. pneumoniae*, also in C.B-17 mice, was moderate and the organisms were present in the respiratory tract for at least 34 days. Yet the lack of pathological changes makes the model unsuitable.

The *Myc. pulmonis*-induced arthritis in *scid* mice can be further investigated by supplementing the animals with various

immune factors or cells. Alternatively, mice with other genetic defects can be studied to help to identify the components of the host response which are critical for protection, or the inflammation and destruction of the joint when infection is established.

ACKNOWLEDGMENTS

This study was supported by grants from the Swedish Medical Research Council, the Karolinska Institute, the Medical Research Foundation, the Tore Nilson Fund for Medical Research, Palle Ferb Foundation and the Swedish Medical Association.

REFERENCES

- 1 Taylor-Robinson D, Gumpel JM, Hill A, Swanell AJ. Isolation of *Mycoplasma pneumoniae* from the synovial fluid of a hypogammaglobulinaemic patient in a survey of patients with inflammatory polyarthritis. Ann Rheum Dis 1978; **37**:180-2.
- 2 Webster ADB, Taylor-Robinson D, Furr PM, Asherson GL. Mycoplasmal (ureaplasma) septic arthritis in hypogammaglobulinaemia. Br Med J 1978; I:478-9.
- 3 Johnston CLW, Webster ADB, Taylor-Robinson D, Rapaport G, Hughes GRV. Primary late-onset hypogammaglobulinaemia associated with inflammatory polyarthritis and septic arthritis due to *Mycoplasma pneumoniae*. Ann Rheum Dis 1983; **42**:108-10.
- 4 Jorup-Rönström C, Ahl T, Hammarström L, Smith CIE, Rylander M, Hallander H. Septic osteomyelitis and polyarthritis with ureaplasma in hypogammaglobulinemia. Infection 1989; 17:301-3.
- 5 Barile MF, Razin S, Tully JG, Whitcomb RF. The mycoplasmas. London: Academic Press, 1979.
- 6 Cassell GH. The pathogenic potential of mycoplasmas: Mycoplasma pulmonis as a model. Rev Infect Dis 1982; 4(Suppl.):518-34.
- 7 Tully JG. Biology of rodent mycoplasmas. In: Bhath PN, Jacoby RO, Morse III HC, New AE, eds. Viral and mycoplasmal infections of laboratory rodents. Effects on biomedical research. London: Academic Press Inc, 1986: Chapter 7.
- 8 Cassell GH, Lindsey JR, Overcash RG, Baker HJ. Murine mycoplasma respiratory disease. Ann NY Acad Sci 1973; 225:395–412.
- 9 Barden JA, Tully JG. Experimental arthritis in mice with Mycoplasma pulmonis. J Bacteriol 1969; 100:5-10.
- 10 Lindsey JR, Cassell GH, Davidson MK. Mycoplasmal and other bacterial diseases of the respiratory system. In: Foster HL, Small JD, Fox JG, eds. The mouse in biomedical research, Vol. 2. New York: Academic Press, 1982:21–33.
- 11 Keystone EC, Taylor-Robinson D, Osborn MF, Ling L, Pope C, Fornasier V. Effect of T-cell deficiency on the chronicity of arthritis induced in mice by *Mycoplasma pulmonis*. Infect Immun 1980; 27:192-6.
- 12 Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in mice. Nature 1983; 301:527-30.

- 13 Bosma MJ, Carroll AM. The scid mouse mutant: definition, characterization, and potential uses. Ann Rev Immunol 1991; 9:323-50.
- 14 Lutsky II, Organick AB. Pneumonia due to Mycoplasma in gnotobiotic mice. I. Pathogenicity of Mycoplasma pneumoniae, Mycoplasma salivarium, and Mycoplasma pulmonis for the lungs of conventional and gnotobiotic mice. J Bacteriol 1966; 92:1154-63.
- 15 Davidson MK, Davis JK, Lindsey JR. Lesions and intrapulmonary killing of *Mycoplasma pulmonis* in *scid/scid, bg/bg*, and *bg-nu/bgnu* mice. 9th International Congress of the International Organization for Mycoplasmology, Ames, Iowa 1992; PS2/26.
- 16 Kohn DF, Magill LS, Chinookoswong N. Localization of Mycoplasma pulmonis in cartilage. Infect Immun 1982; 35:730-3.
- 17 Kohn DF, Chinookoswong N. Detection of *Mycoplasma pulmonis* in arthritic joints of rats by indirect immunoperoxidase staining. Infect Immun 1989; 57:1321–3.
- 18 Dorshkind K, Keller GM, Phillips RA, Miller RG, Bosma GC, O'Toole M, Bosma J. Functional status of cells from lymphoid and myeloid tissues in mice with severe combined immunodeficiency disease. J Immunol 1984; 132:1804–8.
- 19 Keystone EC, Cunningham AJ, Metcalfe A, Kennedy M, Quinn PA. Role of antibody in the protection of mice from arthritis induced by *Mycoplasma pulmonis*. Clin Exp Immunol 1982; **47**:253–9.
- 20 Keystone EC, Taylor-Robinson D, Pope C, Taylor G, Furr P. Effect of inherited deficiency of the fifth component of complement on arthritis induced in mice by *Mycoplasma pulmonis*. Arthritis Rheum 1978; 21:792-7.
- 21 Taylor-Robinson D, Schlorlemmer HU, Furr PM, Allison AC. Macrophage secretion and the complement cleavage product C3a in the pathogenesis of infections by mycoplasmas and L-forms of bacteria and in immunity to these organisms. Clin Exp Immunol 1978; 33:486-94.
- 22 Harwick HJ, Mahoney AD, Kalmanson GM, Guze LB. Arthritis in mice due to infection with *Mycoplasma pulmonis*. II. Serological and histological features. J Inf Dis 1976; 133:103–12.
- 23 Dorshkind K, Pollack SB, Bosma MJ, Phillips RA. Natural killer (NK) cells are present in mice with severe combined immunodeficiency (scid). J Immunol 1985; 134:3798-801.
- 24 Tizard I. Resistance to tumours. In: Veterinary immunology, an introduction, 4th edn. Philadelphia: WB Saunders Co., 1992:188– 91.
- 25 Cole BC, Golightly-Rowland L, Ward JR. Arthritis of mice induced by *Mycoplasma pulmonis*: humoral antibody and lymphocyte responses of CBA mice. Infect Immun 1975; 12:1083–92.
- 26 Naot Y, Davidson S, Lindenbaum ES. Role of mitogenicity in pathogenicity of mycoplasmas for murine hosts. Ann Microbiol (Inst Pasteur) 1984; 135A:95-101.
- 27 North RJ, Izzo AA. Granuloma formation in severe combined immunodeficient (SCID) mice in response to progressive BCG infection. Am J Pathol 1993; 142:1959-66.